002 Therapeutic lag in relapsing multiple sclerosis. (29th July 2019)

• Record Type: Journal Article
• Authors: Roos, Izanne; Frascoli, Federico; Lechner-Scott, Jeannette; McCombe, Pamela; Macdonell, Richard; Butzkueven, Helmut; Malpas, Charles; Kalincik, Tomas
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 90(2019)e7
• Page Start: A1
• Page End: A1
• Publication Date: 2019-07-29
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2019-anzan.2
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Introduction: In multiple sclerosis (MS), treatment start or switch is prompted disease activity, often represented by relapses. Immunomodulatory therapies have potent effects on relapse rates but the time required to attain maximal effect is unclear. We aim to develop a method that allows identification of the time to full clinically manifest effect of treatment on relapses. Methods: Data from MSBase, a multinational MS registry, were used. Inclusion criteria consisted of patients with remitting relapsing MS or clinically isolated syndrome (CIS), minimum 3-year pre-treatment follow up, 1-year treatment persistence, yearly review and availability of the minimum dataset. Stratified by therapy, density curves representing relapses occurrence were created. The first local minimum of the first derivative after treatment start was identified, representing stabilisation of treatment effect. Similar method was utilised to calculate the last pre-treatment point of stabilisation. Annualised relapse rates (ARR) were compared in the pre-treatment pre stabilisation and post-treatment post stabilisation periods. Results: 4979 eligible patients with 6218 treatment epochs were identified for analysis. Time, in years, to treatment effect was shortest for interferon beta-1a sc (0.22, 0.19–0.22), interferon beta-1b (0.24, 0.21–0.24) and fingolimod (0.26, 0.23–0.26) and longest for dimethyl fumarate (0.54, 0.51–0.54) and glatiramer acetate (0.62, 0.60–0.62). Significant differences in pre vs post treatment ARR were present for patients on natalizumab, fingolimod and dimethyl fumarate. A sequential analysis confirmed outcome stability after approximately 1000 recorded number of events. Conclusions: We have developed a method to objectively quantify time from commencing therapy to its full effect. Time to full effect varies among therapies.